TNF-α’s Role in Immunometabolism
Immune and metabolic responses are tightly integrated to maintain balance in organisms, with tumor necrosis factor-alpha (TNF-α) playing a key role in both processes.
Obesity Fuels Rise in Nonalcoholic Fatty Liver Disease
The rise in obesity has led to increased metabolic diseases like insulin resistance, type 2 diabetes, and nonalcoholic fatty liver disease (NAFLD), the most common chronic liver disease globally
Alcohol and Metabolic Syndrome: A Synergistic Risk for Chronic Liver Disease
Alcohol use and metabolic syndrome (MetS) are both highly prevalent and often co-exist, contributing independently and synergistically to chronic liver disease and hepatocellular carcinoma (HCC).
Weight Management Program Sustains 36% Diabetes Remission at 24 Months
The DiRECT trial examined the impact of a primary care-led weight management program on type 2 diabetes remission over two years.
Meeting the Challenge of MASH
Worldwide, MASH is increasing, and this is a challenge for patients and clinicians. Addressing this challenge is the development of evidence-based recommendations for the assessment and management of patients who live with MASLD and MASH.
Comorbidity: Health Benefits of Modest Weight Loss
Recent findings suggest that even small amounts of weight loss can lead to significant improvements in glycemic measures, triglycerides, blood pressure, and HDL cholesterol, which are crucial for diabetes prevention.
Global Obesity Crisis: Stigma and Inadequate Care Persist Despite Affecting 2 Billion Adults
The obesity crisis is a global health challenge, affecting over 2 billion adults and nearly tripling in prevalence over the past 40 years. Despite its significant impact as a chronic, complex disease driving non-communicable diseases (NCDs), obesity remains inadequately addressed in health systems worldwide.
Renaming Nonalcoholic Fatty Liver Disease to Reflect Disease Complexity
The term “nonalcoholic fatty liver disease” (NAFLD) has not been revisited since it was introduced in 1980, despite the disease’s rising prevalence and significant clinical and economic impact.
Genetic Insights Offer New Hope for Nonalcoholic Fatty Liver Disease Treatment
Despite the prevalence of nonalcoholic fatty liver disease (NAFLD), the most common liver disease worldwide, there are currently no approved pharmacotherapies for NAFLD. This review explores the potential and challenges of using genetic findings to enhance and expedite the development of effective treatments for NAFLD.